Though it’s not getting the frenzy of media attention it received in the past several months, the World Health Organization and Center for Disease Control say the H1N1 (swine flu) is still spreading worldwide and remains a constant threat. Pharmaceutical companies are working to overcome modern challenges as the virus mutates, and are racing to develop and manufacture enough vaccines to protect citizens on mass scales.

Adamis Pharmaceuticals Corp. operates through its two wholly owned subsidiaries as a specialty pharmaceutical company. The company today announced that its Adamis Viral Therapies subsidiary’s patented vaccine technology induces immunity against the influenza virus by targeting and attacking regions of the virus that aren’t subject to mutation.

According to the company, the influenza virus rapidly mutates, generating a need for reformulated vaccines every year. As a result, conventional vaccines that stimulate antibody responses become ineffective as the virus mutates.

Through the combination of DNA immunization and genetic cell programming, Adamis’ technology differs from conventional vaccines by targeting the induction of T cell immunity, focusing on the regions of the virus that remain constant among the mutating strains of the virus.

In its press release, the company notes that there are regions of several strains of the virus that remain resistant to mutation, including the avian (H5N1) and swine flu viruses. These regions have resisted change since the Spanish Flu pandemic of 1918, and for this reason, Adamis focuses on those unchanged regions to bring about what it hopes will be a breakthrough in vaccine technology.

Through a mouse study, Adamis demonstrated that its vaccine was effective in inducing long-lasting memory T cell responses with the capability to kill virus-infected cell and limit infection.

“We believe this technology is an excellent way to induce T cell immunity and, in addition to influenza, our technology may prove to be efficacious in the treatment of a variety of diseases including chronic hepatitis,” Adamis CEO Dennis J. Carlo, Ph.D., stated.